ClinicalTrials.gg
RecruitingNCT07040904MLXUpdated May 11, 2026

Mindfulness to Enhance Cognitive Health in Latino Older Adults

An interventional study of mindfulness in Mindfulness and Alzheimer's Disease Related Dementia, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Alzheimer Disease by Washington University School of Medicine — 8 open to participants now, 15 under way, 5 of them phase 3. Alzheimer Disease · Washington University School of Medicine.

Planned enrollment
11th of 14
60 · median 232
Started
2024
with 4 others
No phase
5 of 25
1 open now
Primary completion
2026-07
later than 1 of 14 live
Registered
23rd of 25
by date

Among the 25 studies in Alzheimer Disease by Washington University School of Medicine, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 with no phase, reaches primary completion later than 1 of the 14 other live ones, and was the 23rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 25 studies in Alzheimer Disease by Washington University School of Medicine are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Alzheimer Disease by Washington University School of Medicine, or all of them as a file.
02

Study summary

The primary objective of the proposed research is to investigate the promise and underlying mechanisms of mindfulness training as a preventative lifestyle intervention to enhance cognitive health in Latino older adults, thereby mitigating risk of Alzheimer's Disease (AD) in a population that may be particularly vulnerable.

Read the detailed description

This proposal rigorously examines the feasibility and mechanisms of action of a novel, culturally-sensitive mindfulness training program developed by the PIs, utilizing EEG methods and theoretically-optimized cognitive control tasks to assess neurocognitive effects. Additionally, blood-based assessment of AD biomarkers will be utilized to test whether biomarker status will moderate the effect of training, such that the neurocognitive benefits will be larger Latino older adults with greater evidence of AD-related pathology. Furthermore, the study will also seek to elucidate the subjective effects of mindfulness training on daily-life experiences using ecological momentary assessment (EMA) methods. The study will utilize a mixed between and within-subject design involving longitudinal (pre vs. post-training) assessment and a wait-list control group. 60 Latino older adults will first complete a baseline assessment protocol, followed by randomized assignment to either the mindfulness or wait-list group (N=30 in each group). The mindfulness group will receive 8 weeks of mindfulness training. During this 8-week period participants from both groups will also complete an EMA protocol, consisting of prompts occurring 4x/day on 3 random days per week, assessing subjective mindfulness states, practice experiences, mood, cognition, setting, and activity. Both groups will then return to repeat performance of the same assessment protocol. The assessment protocol involves two testing sessions performed on separate days, each involving completion of the Stroop and AX-CPT task while continuous EEG is recorded. The mindfulness training curriculum utilizes a novel adaptation of the well-validated mindfulness-based stress reduction (MBSR) course, that has been previously validated in focus groups. Participants will meet weekly with an instructor (either in-person or on-line) in classes to receive instructions and practice mindfulness skills. The curriculum embeds core MBSR principles and practices within a culturally-sensitive didactic framework, that includes four key modifications: (1) delivering all instruction in participants native Spanish language; (2) emphasizing/encouraging the connection between mindfulness practices and participants' personal religious beliefs (e.g., "connecting the breath/body to God"), (3) incorporating culturally unique experiences into group activities/exercises (e.g., sharing immigration stories and examining how alterations in perspective can influence meaning and affect), and (4) adding more familial focus to course content (e.g., highlighting how certain skills or practices can benefit the family). In addition to weekly class meetings, participants will also have access to instructional videos and guided audio practices available on their mobile device; on these devices, they will also be periodically prompted to partake in a short mindfulness behavioral task, a 2-minute breath-counting exercise. Finally, all participants will complete a blood draw at the end of the study to determine AD biomarker status. Outcomes will be assessed using EMA measures of daily mindfulness and mood/cognition as well as other qualitative self-report measures assessing the accessibility, utility and feasibility of the mindfulness training curriculum (Aim 1); EEG/ERP measures of state mindfulness and neurocognitive functioning (Aim 2); behavioral metrics of cognitive performance (Aim 2); and moderating role of AD biomarker status (Aim 3).

03

Conditions studied

  • Mindfulness
  • Alzheimer's Disease Related Dementia

Keywords

  • AD Biomarkers
  • Alzheimer's Disease
  • Alzheimer's disease and related dementias
  • cognitive behavioral intervention
  • Mindfulness
  • Mindfulness Training
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hispanic/Latino
  • Age 65 and older
  • Male, female, or non-binary
  • Community living
  • Medically stable and willing to undergo the study procedures
  • No extensive mindfulness training experience

Exclusion criteria

Exclusion Criteria:

  • Clinically unstable psychiatric disorder that requires immediate treatment (e.g., ECT)
  • Medical conditions suggesting significantly shortened lifespan (e.g., cancer) or prohibiting safe participation in the interventions/assessments (e.g., Parkinson's disease, musculoskeletal conditions)
  • Sensory impairment (hearing, vision) preventing participation
  • Current alcohol or substance abuse
  • Current/concurrent cognitive training known to affect neuroplasticity (e.g., brain-training programs), or other interventions expected to affect neuroplasticity significantly (e.g., psychedelics, cholinesterase inhibitors, high-dose sedatives).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Interventions

  • Behavioralmindfulness

    MBSR: Mindfulness Program A novel and culturally-adapted version of the well-validated mindfulness-based stress reduction (MBSR) course will be used for the intervention. The adapted program curriculum embeds core MBSR principles and practices within a culturally responsive didactic framework developed directly from community focus-group feedback. The course will be delivered via a group meeting across 8 weeks, with weekly classes held at a local community center. All classes will be held in hybrid format, with most participants attending in person, but with a live-stream option offered via Zoom.

06

What researchers measure

Primary outcomes

  1. EEG brain markers of cognitive functioning

    EEG indices of cognitive performances evoked by task stimuli and participant responses. ERP components of attention and cognitive control during task performance, focused on target-related P3 amplitude.

    Time frame: Time-frame: 2 time-points - baseline/pre-intervention, and immediately after the intervention

  2. EEG brain markers of cognitive functioning

    EEG indices of cognitive performances evoked by task stimuli and participant responses. ERP components of attention and cognitive control during task performance, focused on cue-related Contingent Negative Variation (CNV).

    Time frame: Time-frame: 2 time-points - baseline/pre-intervention, and immediately after the intervention

  3. AXCPT behavioral performance (reaction time)

    Behavioral performance indices during AXCPT task: AX-CPT - reaction time in milliseconds

    Time frame: Assessed at 2 timepoints: baseline/pre-intervention immediately post-intervention

  4. AXCPT behavioral performance score (accuracy)

    Behavioral performance indices during AXCPT task: AX-CPT - % accuracy AX-CPT --% accuracy

    Time frame: Assessed at 2 timepoints: baseline/pre-intervention immediately post-intervention

  5. Five Facet Mindfulness Questionnaire (FFMQ) score

    Five Facet Mindfulness Questionnaire (FFMQ) is a 39-item self-report inventory used to measure five distinct facets of mindfulness. The five facets are observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience, each rated on a 5-point Likert scale.

    Time frame: Performed during the intervention (3x /week for 8 weeks)

  6. The Mindful Attention Awareness Scale (MAAS) score

    The Mindful Attention Awareness Scale (MAAS) is a 15-item measure of mindfulness that prioritizes assessment of the general tendency to be attentive and aware of experiences in the present moment. It is is rated on a 6-point Likert scale (almost always, very frequently, somewhat frequently, somewhat infrequently, very infrequently, almost never).

    Time frame: Performed during the intervention (3x /week for 8 weeks)

  7. Cognitive and Affective Mindfulness Scale (CAMS-R) score

    Cognitive and Affective Mindfulness Scale (CAMS-R) is used to evaluate symptoms of mindfulness as EMA (ecological momentary assessment) questions. It will be measured in a Likert scale (Not at all, Somewhat, Quite a bit, Almost completely)

    Time frame: Performed during the intervention (3x /week for 8 weeks)

  8. Patient-Reported Outcomes Measurement Information System (Promis) score

    PROMIS (Patient-Reported Outcomes Measurement Information System) are item banks that measure common health outcomes across the domains of physical, mental, and social health.

    Time frame: Performed during the intervention (3x /week for 8 weeks)

  9. National Institutes of Health Toolbox Emotion Battery (NIH-TOOLBOX-EB) score

    National Institutes of Health Toolbox Emotion Battery for English- and Spanish-speaking adults (NIH-TOOLBOX-EB): National Institutes of Health Toolbox Emotion Battery for English- and Spanish-speaking adults (NIH-TOOLBOX-EB) A series of scales that will be rated on a 5-point Likert scale which include: 1. General Life Satisfaction 2. Meaning and Purpose 3. Loneliness 4. Sadness 5. Positive Affect 6. Fear Affect 7. Perceived Stress 8. Resilience Scale 9. Sleep Quality Scale

    Time frame: baseline (pre-intervention) & immediately post-intervention

Secondary outcomes

  1. EEG metrics of mindfulness practice quality

    EEG spectral power (alpha, theta bands) evoked during guided mindfulness state induction

    Time frame: Assessed at 2 timepoints: baseline/pre-intervention immediately post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the data collected in will be preserved through deposition in a public access data repository (i.e., Open Science Framework [OSF]). Raw self-report, transcription, and EMA data will be recoded, scored, and wrangled to "long" format to enhance accessibility and ease of use prior to sharing. All shared data will be deidentified.

Supporting information: Statistical analysis plan, Analytic code

Time frame: Data will be made available one year after data collection begins and updated annually until the award period ends. All data, data wrangling procedures, registrations, and analysis scripts associated with published manuscripts will be organized into an easily accessible subfolder and made available no later than the time of publication acceptance. The data will be available for public access indefinitely, or until new guidelines are released regarding data archival duration.

Access criteria: All data that is uploaded to OSF will be publicly available with no controlled access.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jul 2026, 19 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 19 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Jun 27, 2025
StartActual
Dec 10, 2024
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07040904
Responsible party
Todd Braver (Professor, Washington University School of Medicine) — Principal investigator
First posted
Jun 27, 2025
Start date
Dec 10, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
May 11, 2026

Study contacts

Todd S Braver, Ph.D.
Contact
tbraver@wustl.edu
800-438-0445
Diana Parra Perez, Ph.D.
Contact
parrad@wustl.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion